Tango Therapeutics, Inc. remains a high-risk, high-reward biotech, focused on PRMT5 inhibitors for MTAP-deleted cancers—a large, underserved market opportunity. Disappointing clinical data last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results